FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Pediatr Blood Cancer
; 69(8): e29602, 2022 08.
Article
in En
| MEDLINE
| ID: mdl-35561013
Full text:
1
Database:
MEDLINE
Main subject:
Lymphoma, Large-Cell, Anaplastic
/
Immunoconjugates
Limits:
Adult
/
Child
/
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
Pediatr Blood Cancer
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Year:
2022
Type:
Article
Affiliation country:
United States